Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Randomized, Double-blind Trial to Assess the Safety and Immunogenicity of MTBVAC (BBV169), With BCG Vaccine as a Comparator in Healthy Adolescent and Adult Populations

NCT06997367 is registered in ClinicalTrials.gov with Bharat Biotech International Limited as lead sponsor.

NCT NCT06997367
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06997367 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Randomized, Double-blind Trial to Assess the Safety and Immunogenicity of MTBVAC (BBV169), With BCG Vaccine as a Comparator in Healthy Adolescent and Adult Populations
Lead sponsor
Bharat Biotech International Limited
Phase
Phase 2
Overall status
Active, not recruiting
Start date
March 27, 2025
Completion date
June 30, 2026
Enrollment
164 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

tuberculosis (tb)